Assess whether pediatric studies are necessary or waivable (be9966)

Situation

The desk packet is biosimilar analytical similarity report after a DSMB note on an imbalance that is not yet a signal. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences Pharmacovigilance file.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Pediatric studies are necessary / Waivable using biosimilar analytical similarity report after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• The population in biosimilar analytical similarity report is the one a DSMB note on an imbalance that is not yet a signal named, so Pediatric studies are necessary follows for this Pharmacovigilance file.
• The population in biosimilar analytical similarity report is adjacent only to a DSMB note on an imbalance that is not yet a signal; Waivable is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained a DSMB note on an imbalance that is not yet a signal before biosimilar analytical similarity report arrived; no new Pharmacovigilance path.
• Provenance on biosimilar analytical similarity report after a DSMB note on an imbalance that is not yet a signal is broken; do not pick Pediatric studies are necessary or Waivable yet.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move pediatric studies are necessary for 505(b)(2) development lead.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after a DSMB note on an imbalance that is not yet a signal). The follow-on Pharmacovigilance action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.